Main Newsletter
Mastery Series
Therapy Series
 
Bookmark and Share | Print Article | Items for the Week Previous | All Articles This Week | Next
This article originally posted and appeared in  MedicationAging & DiabetesOncologyInsulinIssue 671

Metformin May Delay Aging and Cancer Progression

Metformin delays aging and cancer progression by reducing the production of....
Advertisement

A research team from the University of Montreal revealed the mechanism of how metformin slows aging and cancer progression. In a study, they found that metformin reduces the production of inflammatory cytokines. These inflammatory cytokines are key players activating the immune system in tissue damage during aging and tumor growth in cancer development.

Dr. Gerardo Ferbeyre and colleagues found that metformin decreases cytokines by disrupting a protein called NF-kB that would normally trigger cytokine activation and the immune system. When cytokines are overproduced, this leads to pathological inflammation that is involved in both the aging and cancer processes.

Dr. Ferbeyre said, "This is an important finding with implications for our understanding on how the normal organism defends itself from the threat of cancer and how a very common and safe drug may aid in treatment of some cancers and perhaps slow down the aging process." He added, "It remains that determining the specific targets of metformin would give us an even better opportunity of profit from its beneficial effects. That's what we want to figure out next." This finding may be an important step in finding a place for metformin therapy in anti-cancer and anti-aging therapy.

"Metformin inhibits the senescence-associated secretory phenotype by interfering with IKK/NF-B activation" Aging Cell, March 2013 

Advertisement


 

Bookmark and Share | Print | Category | Home

This article originally posted 05 April, 2013 and appeared in  MedicationAging & DiabetesOncologyInsulinIssue 671

Past five issues: Issue 766 | Diabetes Clinical Mastery Series Issue 225 | Issue 765 | Diabetes Clinical Mastery Series Issue 224 | Issue 764 |

2015 Most Popular Articles:

Significant Weight Loss and Drop in A1c with New Combo of Lorcaserin and Phentermine
Posted January 16, 2015
ADA Issues New Standards of Medical Care for Diabetes
Posted January 02, 2015
New Guideline Released on Pharmacological Management of Obesity
Posted January 23, 2015
For Your Patients: Practical Advice to Rev Up Your Workouts and Lower Fatigue
Posted January 09, 2015
Dr. Timothy Garvey on Qsymia and Other New Therapies for Weight Loss
Posted January 12, 2015
Phentermine and Topirimate ER (Qsymia) Studied for Type 2 Diabetes Patients
Posted January 15, 2015
Handbook of Diabetes, 4th Ed., Excerpt #25: Specific Circumstances that Affect Diabetes Control
Posted January 04, 2015
New Insulin Glargine 300 Effective in Type 1 Diabetes
Posted January 16, 2015
FDA Approves Maestro Electronic Weight Loss Device
Posted January 23, 2015
New Guidelines Recommend Off-Loading to Increase Likelihood of Diabetic Foot Ulcer Healing
Posted December 26, 2014


Browse by Feature Writer & Article Category.
A. Lee Dellon, MD | Aaron I. Vinik, MD, PhD, FCP, MACP | Beverly Price | Charles W Martin, DD | Derek Lowe, PhD | Dr. Brian Jakes, Jr. | Dr. Fred Pescatore | Dr. Tom Burke, Ph.D | Eric S. Freedland | Evan D. Rosen | Ginger Kanzer-Lewis | Greg Milliger | Kristina Sandstedt | Laura Plunkett | Leonard Lipson, M.A. | Louis H. Philipson | Maria Emanuel Ryan, DDS, PhD | Marilyn Porter, RD, CDE | Melissa Diane Smith | Michael R. Cohen, RPh, MS, ScD, FASHP | Paul Chous, M.A., OD | Philip A. Wood PhD | R. Keith Campbell, Professor, B.Pharm, MBA, CDE | Richard K. Bernstein, MD | Sheri R. Colberg PhD | Sherri Shafer | Stanley Schwartz, MD, FACP, FACE | Steve Pohlit | Steven V. Edelman, M.D. | Timothy S. Hollingshead |

Cast Your Vote
Will you prescribe inhaled insulin (Afrezza) when it becomes available this year?
CME/CE of the Week
Jeffrey Mechanick

Category: General Diabetes
Credits: .75
Search Articles On Diabetes In Control